TY  - JOUR
AU  - Perez-Robles, Raquel
AU  - Hermosilla, Jesus
AU  - Navas, Natalia
AU  - Clemente-Bautista, Susana
AU  - Jimenez-Lozano, Ines
AU  - Cabañas-Poy, Maria Josep
AU  - Ruiz-Trave, Julio
AU  - Hernandez-Garcia, Maria Amparo
AU  - Cabeza, Jose
AU  - Salmeron-Garcia Antonio
PY  - 2022
DO  - 10.1016/j.jpba.2022.115064
UR  - http://hdl.handle.net/10668/22329
T2  - Journal of pharmaceutical and biomedical analysis
AB  - Teduglutide, the active ingredient of the medicine Revestive® (5 mg), is a recombinant therapeutic peptide that mimics the effects of the endogenous glucagon-like peptide 2 (GLP-2). It stimulates intestinal growth, adaptation and function in patients...
LA  - en
PB  - Elsevier BV
KW  - Hospital condition
KW  - Long-term stability study
KW  - Revestive®
KW  - Teduglutide
KW  - Gastrointestinal Agents
KW  - Glucagon-Like Peptide 2
KW  - Humans
KW  - Peptides
KW  - Plastics
KW  - Short Bowel Syndrome
TI  - Tracking the physicochemical stability of teduglutide (Revestive®) clinical solutions over time in different storage containers.
TY  - research article
VL  - 221
ER  -